Answers are grounded in this paper and cite their sources.
Mucocutaneous Behcet's disease is often a therapeutic challenge. Roflumilast has shown promise in other inflammatory dermatological conditions. The objective of this study is to evaluate the characteristics, effectiveness and safety of roflumilast in the treatment of Behçet's Disease-associated aphthosis in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Leal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: